Profile data is unavailable for this security.
About the company
Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The Company is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.
- Revenue in AUD (TTM)339.30k
- Net income in AUD-3.48m
- Incorporated1992
- Employees29.00
- LocationAvecho Biotechnology LtdUnit A8, 2A Westall Road, ClaytonMELBOURNE 3168AustraliaAUS
- Phone+61 39002-5000
- Fax+61 39565-1151
- Websitehttps://avecho.com.au/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wellfully Ltd | 1.31m | -1.34m | 1.48m | 36.00 | -- | -- | -- | 1.13 | -0.003 | -0.003 | 0.0034 | -0.0034 | 0.377 | 0.3166 | 1.57 | -- | -38.36 | -175.88 | -- | -441.84 | 48.61 | -- | -101.74 | -266.08 | 0.2159 | -- | -- | -- | -42.78 | -5.87 | 12.98 | -- | 21.75 | -- |
Cambium Bio Ltd | 128.99k | -2.26m | 3.94m | -- | -- | 1.42 | -- | 30.52 | -0.4599 | -0.4599 | 0.0173 | 0.2327 | 0.0318 | -- | 1.00 | -- | -55.60 | -30.97 | -144.62 | -99.20 | 62.39 | -- | -1,748.79 | -74.07 | -- | -149.70 | 0.1443 | -- | -- | -- | -33.72 | -- | -- | -- |
Vectus Biosystems Ltd | 86.39k | -2.49m | 4.26m | -- | -- | 1.80 | -- | 49.27 | -0.0467 | -0.0467 | 0.0016 | 0.0445 | 0.0191 | -- | -- | -- | -54.95 | -96.22 | -68.14 | -691.17 | -- | -- | -2,880.80 | -27,693.78 | -- | -439.76 | 0.00 | -- | 69,287.50 | 97.87 | 13.64 | -- | -- | -- |
Invex Therapeutics Ltd | 1.70m | -1.64m | 5.56m | -- | -- | 0.9777 | -- | 3.26 | -0.0218 | -0.0218 | 0.0227 | 0.0757 | 0.1178 | -- | 7.95 | -- | -11.35 | -15.73 | -12.20 | -16.55 | -- | -- | -96.35 | -535.37 | -- | -- | 0.00 | -- | 35.66 | 566.05 | 78.81 | -- | -- | -- |
Holista Colltech Limited | 5.46m | -4.64m | 5.58m | 3.00 | -- | -- | -- | 1.02 | -0.0166 | -0.0166 | 0.0196 | -0.0094 | 1.48 | 3.54 | 5.39 | -- | -125.43 | -42.59 | -1,528.79 | -63.58 | 51.69 | 56.37 | -85.04 | -39.27 | 0.2094 | -282.55 | -- | -- | -27.82 | -5.65 | -230.77 | -- | -37.12 | -- |
Neuroscientific Biopharmaceuticals Ltd | 2.39m | 324.21k | 5.64m | -- | 17.18 | 1.05 | 13.57 | 2.36 | 0.0023 | 0.0023 | 0.0165 | 0.037 | 0.4458 | -- | 48.82 | -- | 6.04 | -46.72 | 6.46 | -51.16 | -- | -- | 13.56 | -199.33 | -- | 33.42 | 0.00 | -- | -52.76 | 82.13 | 130.34 | -- | -37.50 | -- |
Avecho Biotechnology Ltd | 339.30k | -3.48m | 6.34m | 29.00 | -- | 1.50 | -- | 18.68 | -0.0012 | -0.0012 | 0.0001 | 0.0013 | 0.0693 | 4.26 | 0.7043 | -- | -71.20 | -47.08 | -105.46 | -55.25 | -45.60 | 78.67 | -1,026.91 | -156.43 | 3.48 | -- | 0.0316 | -- | -58.07 | -19.42 | -46.71 | -- | -- | -- |
Zelira Therapeutics Ltd | 1.02m | -36.57m | 9.08m | 8.00 | -- | -- | -- | 8.87 | -3.22 | -3.22 | 0.0902 | -0.3979 | 0.0524 | 0.0609 | 5.06 | -- | -188.05 | -46.98 | -246.20 | -50.16 | 91.73 | -- | -3,587.90 | -1,063.82 | 0.424 | -6.78 | 3.35 | -- | -82.72 | -35.59 | -556.18 | -- | -- | -- |
Island Pharmaceuticals Ltd | 4.72k | -2.86m | 10.15m | -- | -- | 6.68 | -- | 2,150.66 | -0.0318 | -0.0318 | 0.00005 | 0.012 | 0.002 | -- | 0.0104 | -- | -124.17 | -- | -173.37 | -- | -- | -- | -60,684.75 | -- | -- | -544.58 | 0.2174 | -- | -57.45 | -- | -1.20 | -- | -- | -- |
Adalta Ltd | 1.78m | -5.38m | 11.52m | -- | -- | 5.57 | -- | 6.45 | -0.0111 | -0.0111 | 0.0036 | 0.0034 | 0.2682 | -- | 0.7681 | -- | -80.88 | -66.85 | -203.94 | -114.23 | -- | -- | -301.55 | -175.59 | -- | -51.02 | 0.5712 | -- | -49.47 | -13.04 | -10.93 | -- | -18.22 | -- |
Algorae Pharmaceuticals Ltd | 125.20k | -2.10m | 11.81m | -- | -- | 3.92 | -- | 94.34 | -0.0013 | -0.0013 | 0.00008 | 0.0018 | 0.0338 | -- | 1.81 | -- | -56.60 | -47.73 | -61.85 | -54.26 | -- | -- | -1,673.77 | -865.45 | -- | -115.69 | 0.00 | -- | 197.95 | -30.46 | 0.5741 | -- | -- | -- |
Chimeric Therapeutics Ltd | 0.00 | -12.53m | 12.51m | -- | -- | 4.97 | -- | -- | -0.0136 | -0.0136 | 0.00 | 0.0028 | 0.00 | -- | -- | -- | -66.56 | -- | -194.88 | -- | -- | -- | -- | -- | -- | -58.48 | 0.5228 | -- | -- | -- | 50.86 | -- | -- | -- |